New Strategic Partnership to Boost Pharmaceutical Procurement
Integrated Ventures Inc. (OTCQB: INTV) has recently shared an exciting update about its future operations, having formed a crucial partnership through its subsidiary, MedWell USA, LLC. This agreement is specifically designed to enhance the procurement process for Semaglutide, a key product in the weight management market.
MedWell USA's Expansion
This partnership establishes MedWell USA as a Procurement Agent for Semaglutide, a medication renowned for its effectiveness in promoting weight loss and management. MedWell USA plans to implement comprehensive marketing efforts to engage health providers, wellness clinics, and gyms in various states, aiming to carve out a significant presence in the expanding health and wellness sector.
Diving into Semaglutide's Market Potential
Semaglutide is classified as a GLP-1 receptor agonist and is well-regarded for its role in supporting weight loss initiatives. The market for Semaglutide is rapidly changing, with projections suggesting that it may surpass $10.6 billion globally by the end of the decade, indicating a substantial compound annual growth rate (CAGR) of 14.5%.
MedWell USA: A B2B Procurement Agent
This strategic partnership empowers MedWell USA to connect health and wellness clinics with reputable pharmaceutical suppliers. By facilitating these connections, MedWell USA will not only improve access to quality Semaglutide but also enhance clinics’ ability to provide effective weight management solutions for their patients.
Insights from Integrated Ventures' CEO
Steve Rubakh, CEO of Integrated Ventures Inc., shared his enthusiasm about the strategic agreement, stating, "We are excited to announce this pivotal MSO agreement that empowers MedWell USA to play a crucial role in the procurement and expansion of Semaglutide." His comments reflect the company’s commitment to seizing this opportunity to deliver high-quality pharmaceutical options to health and wellness providers.
Plans for Expansion Beyond Semaglutide
Looking ahead, Integrated Ventures Inc. is preparing to sign additional agreements that will position MedWell USA as a Procurement Agent for Tirzepatide. This alternative GLP-1 medication helps manage appetite and stabilizes blood sugar levels, supporting long-term weight loss. The broader vision for MedWell USA includes a strategy focused on both pharmaceutical and medical supply distribution.
Establishing Trust in the Market
With an initial focus on Semaglutide, MedWell USA aims to become a trusted partner in the healthcare and wellness industry. By fostering strong relationships with health providers and pharmaceutical distributors, the organization is looking to facilitate large-scale procurements of safe and effective pharmaceutical products that meet the needs of medical practitioners and their patients.
About Integrated Ventures, Inc.
Integrated Ventures, Inc. is a diversified holdings company dedicated to investment and development in markets with significant potential for growth. The company is actively involved in:
- Digital currency mining and hosting operations.
- MedWell USA, LLC’s initiatives in B2B procurement targeting medical offices and wellness clinics.
- MedWell Direct, LLC, which offers telemedicine platforms that connect consumers with licensed healthcare professionals for weight management.
- MedWell Facilities, LLC, managing real estate developments aimed at attracting health-focused tenants.
Contact Information
For any further inquiries, you can reach Integrated Ventures at (215) 613-9898 or contact them via email at sr@integratedventures.io.
Frequently Asked Questions
What is MedWell USA's primary focus?
MedWell USA primarily focuses on the procurement and marketing of pharmaceuticals, particularly Semaglutide, for health and wellness providers.
What does the agreement with MedWell USA involve?
The agreement allows MedWell USA to function as a Procurement Agent for Semaglutide, facilitating connections between clinics and reliable pharmaceutical suppliers.
Who leads Integrated Ventures?
Steve Rubakh is the CEO of Integrated Ventures Inc.
What other areas does Integrated Ventures operate in?
The company is involved in digital currency mining, telemedicine services, and managing real estate with a focus on health and wellness.
What is the expected market growth for Semaglutide?
The worldwide market for Semaglutide is expected to exceed $10.6 billion by 2028, with a compound annual growth rate of 14.5%.